June 17, 2020 / 11:46 AM / 19 days ago

BRIEF-TG Therapeutics Completes Rolling Submission Of New Drug Application To U.S. FDA

June 17 (Reuters) - TG Therapeutics Inc:

* TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UMBRALISIB AS A TREATMENT FOR PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA OR FOLLICULAR LYMPHOMA

* TG THERAPEUTICS - BLA/NDA SUBMISSION FOR U2 IN CHRONIC LYMPHOCYTIC LEUKEMIA TARGETED BY END OF YEAR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below